Drug Profile
Anti-PSCA CAR-T cell therapy - City of Hope National Medical Center/Mustang Bio
Alternative Names: Anti prostate stem cell antigen-CAR-T cell therapy - City of Hope Medical Center/Mustang Bio; Autologous Anti-PSCA(dCH2)BBz-CAR T-cells; Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells; CAR-T cells - Mustang Bio; MB 105; MB-105 PSCA CAR; PSCA(dCH2)BBzeta-CAR T-cells; PSCA‐targeted CAR T cell therapyLatest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Developer City of Hope National Medical Center; Mustang Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
- Preclinical Bladder cancer
- No development reported Gastric cancer; Glioblastoma; Pancreatic cancer
Most Recent Events
- 02 Jun 2023 Final adverse events and efficacy data from a phase I trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 24 May 2023 Phase-I clinical trials in Prostate cancer (In adults, In the elderly, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (IV) (NCT05805371)
- 16 Mar 2023 Anti-PSCA CAR-T cell therapy is still in phase I trials for Prostate cancer in USA